Expand ALGS Menu
ALGS MENU

ALGS Latest Press Releases

-- December 12, 2025 --

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 8:00 AM

-- December 11, 2025 --

Aligos Therapeutics Presents Positive Data at HEP-DART 2025 Globe Newswire 8:00 AM

-- November 14, 2025 --

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 8:00 AM

-- November 10, 2025 --

Aligos Therapeutics Presents Positive Data at The Liver Meeting 2025 Globe Newswire 8:00 AM

-- November 6, 2025 --

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results Globe Newswire 8:30 AM

-- November 4, 2025 --

Aligos Therapeutics to Present at Upcoming Investor Conferences Globe Newswire 8:30 AM

-- October 30, 2025 --

Aligos Therapeutics to Announce 3rd Quarter 2025 Financial Results on November 6, 2025 Globe Newswire 8:30 AM

-- October 17, 2025 --

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 8:30 AM

-- October 16, 2025 --

Aligos Therapeutics Receives USAN Council Approval for pevifoscorvir sodium as Nonproprietary Name for ALG-000184 Globe Newswire 8:30 AM

-- October 14, 2025 --

Aligos Therapeutics to Present at the H.C. Wainwright Liver Disease Conference Globe Newswire 8:30 AM

-- October 7, 2025 --

Aligos Therapeutics Announces Eight Abstracts Accepted at The Liver Meeting 2025 Globe Newswire 8:30 AM

-- September 3, 2025 --

Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting Globe Newswire 4:05 PM

-- September 2, 2025 --

Aligos Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference Globe Newswire 4:05 PM

-- August 20, 2025 --

Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Ramn Polo as Senior Vice President, Head of Global Regulatory Affairs Globe Newswire 8:30 AM

-- August 15, 2025 --

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 8:30 AM

-- August 13, 2025 --

Aligos Therapeutics Announces First Subject Dosed in the Phase 2 B-SUPREME Study of ALG-000184 in Subjects with Chronic HBV Infection Globe Newswire 8:30 AM

-- August 6, 2025 --

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results Globe Newswire 4:05 PM

-- July 30, 2025 --

Aligos Therapeutics to Announce 2nd Quarter 2025 Financial Results on August 6, 2025 Globe Newswire 4:05 PM
Market Data Delayed 15 Minutes